Your browser doesn't support javascript.
Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.
Bankova, Andriyana K; Pasin, Chloé; Huang, Alice; Cicin-Sain, Caroline; Epp, Selina; Audige, Annette; Mueller, Nicolas J; Nilsson, Jakob; Vilinovszki, Oliver; Nair, Gayathri; Wolfensberger, Nathan; Hockl, Philipp; Schanz, Urs; Trkola, Alexandra; Kouyos, Roger; Hasse, Barbara; Zinkernagel, Annelies S; Manz, Markus G; Abela, Irene A; Müller, Antonia M S.
  • Bankova AK; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Pasin C; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Huang A; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Cicin-Sain C; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Epp S; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Audige A; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Mueller NJ; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Nilsson J; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Vilinovszki O; Department of Immunology, University Hospital Zürich, Zürich, Switzerland.
  • Nair G; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Wolfensberger N; Department of Internal Medicine, University Hospital Zürich, Zürich, Switzerland.
  • Hockl P; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Schanz U; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Trkola A; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Kouyos R; Department of Medical Oncology and Hematology, University Hospital Zürich, Zürich, Switzerland.
  • Hasse B; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Zinkernagel AS; Institute of Medical Virology, University of Zürich, Zürich, Switzerland.
  • Manz MG; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Abela IA; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
  • Müller AMS; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zürich, Zürich, Switzerland.
Br J Haematol ; 2022 Nov 16.
Article in English | MEDLINE | ID: covidwho-2251131
ABSTRACT
Allogeneic haematopoietic cell transplantation (allo-HCT) recipients show impaired antibody (Ab) response to a standard two-dose vaccination against severe acute respiratory syndrome coronavirus-2 and currently a third dose is recommended as part of the primary vaccination regimen. By assessing Ab titres 1 month after a third mRNA vaccine dose in 74 allo-HCT recipients we show sufficient neutralisation activity in 77% of the patients. Discontinuation of immunosuppression before the third vaccine led to serological responses in 50% of low responders to two vaccinations. Identifying factors that might contribute to better vaccine responses in allo-HCT recipients is critical to optimise current vaccination strategies.
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bjh.18562

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Topics: Vaccines Language: English Year: 2022 Document Type: Article Affiliation country: Bjh.18562